AI-Guided immunotherapy aims to stop liver cancer recurrence
NCT ID NCT07379489
First seen Feb 01, 2026 · Last updated May 21, 2026 · Updated 17 times
Summary
This study tests whether a deep learning model can identify which liver cancer patients benefit from immunotherapy (PD-1 inhibitors) after surgery to prevent the cancer from returning. About 300 adults who had their liver cancer completely removed will be followed to see if the AI-guided treatment improves disease-free survival. The goal is to personalize adjuvant therapy and reduce recurrence.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.